Share


The case for action on climate change is clear. We’re taking positive steps to reduce our carbon footprint. 

In 2023, the Intergovernmental Panel on Climate Change (IPCC) reiterated the need for urgent action to avert the most severe impacts of climate change1. The World Health Organisation (WHO) has identified climate change as the single biggest threat to human health2. Whether it’s heightened exposure to a longer, more severe allergy season or the impact of increased emissions associated with air pollution and climate change on breathing, people’s everyday health is already being directly and indirectly impacted by climate change. The impact is only set to intensify unless urgent action is taken.

We have set greenhouse gas (GHG) emissions reductions goals aligned to the Intergovernmental Panel on Climate Change (IPCC) pathway to 1.5°C and aim to achieve net zero carbon emissions from source to sale by 2040, aligned to guidance from The Climate Pledge and Race to Zero. Haleon also works to raise awareness of the linkages between climate change, air pollution, and health, and has joined the Alliance for Clean Air.

We aim to:

  • Reduce our net Scope 1 and 2 carbon emissions by 100% by 2030 vs a 2020 baseline3.
  • Reduce our Scope 3 carbon emissions from source to sale by 42% by 2030 vs a 2022 baseline4, 5
  • Achieve Net Zero carbon emissions from source to sale by 2040, aligned to guidance from The Climate Pledge and Race to Zero5.

We continue to improve the data collection processes used to measure and track our Scope 3 emissions footprint. We have updated our baseline year for our Scope 3 goal from 2020 to 2022, when we became a standalone business, as the 2022 data used to calculate and substantiate our value chain emissions has greater availability and accuracy.  


2023 Performance Highlight:


48%

reduction in net Scope 1 and 2 carbon emissions versus 20206


We've been making significant progress in reducing our net Scope 1 and 2 carbon emissions. This has been achieved by switching to 100% renewable electricity across all our sites which we directly control, as well as through the concerted action we’ve taken to decarbonise our manufacturing operations and drive energy efficiency. Our Scope 1 and 2 programme is focused on absolute reduction of 95% of emissions from our operations, driven primarily by conversion to renewable energy sources.

Across Scope 3 carbon emissions, over half of our cradle-to-grave carbon emissions are driven by the ingredients, packaging, and services we buy and use to make our products. Key contributors to our carbon emissions from purchased goods and services include certain packaging materials and active pharmaceutical ingredients in our products.

We will focus on systematically reducing our carbon emissions by:

  • Continuing to decarbonise our manufacturing operations by converting to renewable energy sources and driving energy efficiency.
  • Reducing or removing carbon emission-intensive raw materials or packaging materials, and/or replacing them with a lower footprint alternative.
  • Working with key suppliers and through industry coalitions to support decarbonisation in our upstream supply chain.

 



Harnessing solar power at our Oak Hill site

We launched a long-term Power Purchase Agreement (PPA) at our facility in Oak Hill, New York, which manufactures oral health products including Sensodyne and Pronamel for the North American market. We’re partnering with Ameresco Solar Energy Solutions to supply Oak Hill with 70% of its electricity from a dedicated off-site solar park.


Achieving carbon neutrality at our manufacturing site in Suzhou

Our Suzhou site in China is our first carbon neutral manufacturing site, meaning it has achieved net zero Scope 1 and 2 carbon emissions through carbon reduction, renewable electricity and carbon offsetting. It has been certified by Bureau Veritas Certification Beijing Co., Ltd. in accordance with the PAS 2060 standard. 


Raising awareness of the impact climate change has on everyday health 

We work with Forum for the Future and industry peers as a co-founding partner of the Climate and Health Coalition to highlight the human health impacts of climate change and mobilise action to deliver benefits for both climate and health.

Through the creation of The Clean Breathing Institute, we support pharmacists to give trusted advice to their patients on how to mitigate the impact of air pollution on respiratory health.


AR6 Synthesis Report: Climate Change 2023 — IPCC

Climate change and health (who.int)

3 Our goal to reduce net Scope 1 and 2 carbon emissions by 100% by 2030 is underpinned by a 95% absolute reduction target. The 2020 baseline reporting period is the calendar year.

4 The 2022 baseline reporting year is the calendar year.

5 Our Net Zero and Scope 3 carbon emissions targets span all carbon emission categories from source to sale (excluding GHG-protocol categories 6, 7, 10-15). It covers mandatory Scope 3 upstream and downstream emissions. It excludes indirect consumers use-phase emissions, such as emissions associated with water used with our products. 

6 The 2023 reporting period is 1 December 2022 to 30 November 2023.